Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | MARS2 | Q96GW9 | 1/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | RPLP1 | P05386 | 1/20 | 0.65 |
| ▸ | RPLP0 | P05388 | 1/20 | 0.65 |
| ▸ | RPS17 | P08708 | 1/20 | 0.65 |
| ▸ | RPSA | P08865 | 1/20 | 0.65 |
| ▸ | RPS2 | P15880 | 1/20 | 0.65 |
| ▸ | RPL35A | P18077 | 1/20 | 0.65 |
| ▸ | RPL7 | P18124 | 1/20 | 0.65 |
| ▸ | RPL17 | P18621 | 1/20 | 0.65 |
| ▸ | RPS4Y1 | P22090 | 1/20 | 0.65 |
| ▸ | RPS3 | P23396 | 1/20 | 0.65 |
| ▸ | RPS12 | P25398 | 1/20 | 0.65 |
| ▸ | RPL13 | P26373 | 1/20 | 0.65 |
| ▸ | RPL10 | P27635 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16093313 | 0.88 | LMNA (0.74) | LMNACYP3A4TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL16009977 | 0.84 | CYP3A4 (0.72) | LMNACYP3A4TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL12850350 | 0.84 | CYP3A4 (0.72) | LMNACYP3A4TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL4744337 | 0.84 | CYP3A4 (0.72) | LMNACYP3A4TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL16011473 | 0.84 | CYP3A4 (0.91) | LMNACYP3A4TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL5855268 | 0.83 | LMNA (0.68) | LMNACYP3A4TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL16011501 | 0.83 | CYP3A4 (0.71) | LMNACYP3A4TSHRALDH1A1SMN1; SMN2 | |
| Chloramphenicol SCHEMBL49057 | 0.83 | LMNA (1.00) | LMNACYP3A4TSHRALDH1A1SMN1; SMN2 | |
| Chloramphenicol SCHEMBL4262903 | 0.83 | LMNA (1.00) | LMNACYP3A4TSHRALDH1A1SMN1; SMN2 | |
| Chloramphenicol SCHEMBL4295048 | 0.83 | LMNA (1.00) | LMNACYP3A4TSHRALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| CN-117597327-A | Pharmaceutical preparation | 第一波动生物制药股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11744812-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230201143-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2023118074-A1 | COMPRESSIBLE AND FREE FLOWING CO-PROCESSED MESOPOROUS SILICA | UNIVERZA V LJUBLJANI (SI) | 2023-06-29 | — | — | WO | disclosed |
| US-20230190684-A1 | METHODS OF TREATING COVID-19 WITH A NICLOSAMIDE COMPOUND | FIRST WAVE BIO, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FIRST WAVE BIO, INC. | 2023-03-30 | — | — | US | disclosed |
| US-11564896-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20220000812-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2022-01-06 | — | — | US | disclosed |
| US-10744103-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FIRST WAVE BIO, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| US-20200197339-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-06-25 | — | — | US | disclosed |
| US-20200197340-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-06-25 | — | — | US | disclosed |
| US-20200147013-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-05-14 | — | — | US | disclosed |
| US-20200147012-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-05-14 | — | — | US | disclosed |
| US-20190298670-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | MONTERESEARCH S.R.L. (IT) | 2019-10-03 | — | — | US | disclosed |
| US-10292951-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FIRST WAVE BIO, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| EP-3344274-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | First Wave Bio, Inc. (US) | 2018-07-11 | — | — | EP | disclosed |
| WO-2017040864-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | First Wave Biopharma (US) | 2017-03-09 | — | — | WO | disclosed |
| US-20170056347-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200147012-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | LMNA 3221/4885CYP3A4 1499/4885TSHR 4852/4885 |
| US-20200197339-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | LMNA 3180/4885CYP3A4 1506/4885TSHR 4852/4885 |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | LMNA 3221/4885CYP3A4 1499/4885TSHR 4852/4885 |
| US-10744103-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FH, CS, ECHS1 | LMNA 3221/4885CYP3A4 1499/4885TSHR 4852/4885 |
| US-20190298670-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | LMNA 3180/4885CYP3A4 1506/4885TSHR 4852/4885 |
| US-20230190684-A1 | METHODS OF TREATING COVID-19 WITH A NICLOSAMIDE COMPOUND | ACE2, ACE, MME | LMNA 3278/4885CYP3A4 141/4885TSHR 4004/4885 |
| US-20200197340-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | LMNA 3221/4885CYP3A4 1499/4885TSHR 4852/4885 |
| US-10292951-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FH, CS, ECHS1 | LMNA 3180/4885CYP3A4 1506/4885TSHR 4852/4885 |
| US-11744812-B2 | Methods of treatment | ACE2, ACE, SI | LMNA 2771/4885CYP3A4 212/4885TSHR 3982/4885 |
| US-20230201143-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | LMNA 2903/4885CYP3A4 209/4885TSHR 4477/4885 |
| US-11564896-B2 | Methods of treatment | ACE2, ACE, SI | LMNA 2903/4885CYP3A4 209/4885TSHR 4477/4885 |
| US-20170056347-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | LMNA 3180/4885CYP3A4 1506/4885TSHR 4852/4885 |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FH, IDH2, ECHS1 | LMNA 3896/4885CYP3A4 1035/4885TSHR 4789/4885 |
| US-20220000812-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | LMNA 3180/4885CYP3A4 1506/4885TSHR 4852/4885 |
| US-20200147013-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | LMNA 3180/4885CYP3A4 1506/4885TSHR 4852/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | LMNA 3341/4885CYP3A4 1393/4885TSHR 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.